Research programme: radioprotectants - RxBio

Drug Profile

Research programme: radioprotectants - RxBio

Alternative Names: DBIBB; Rx 100; RX100

Latest Information Update: 04 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Tennessee
  • Developer RxBio
  • Class Benzoic acids; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Lysophosphatidic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gastric damage; Radiation injuries

Most Recent Events

  • 29 Jan 2015 Pharmacodynamics data from preclinical trial in Radiation injuries released by RxBio
  • 28 Sep 2011 RxBio receives a $US15 million contract from the US Biomedical Advanced Research and Development Authority for the development of RX 100 in radiation-induced gastrointestinal injury
  • 16 Sep 2009 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top